Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Gujam, Fadia J A ^a,c   Going, James J ^a   Mohammed, Zahra M A ^b   Orange, Clare ^a   Edwards, Joanne ^c   McMillan, Donald C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b University Departments of Pathology Faculty of Veterinary Medicine Almukhtar University   (Libyan Arab Jamahiriya)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD VESSEL; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; TISSUE SECTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; AGED; BREAST NEOPLASMS; METABOLISM; MIDDLE AGED; NEOPLASM INVASIVENESS; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL; VASCULARIZATION;

BLOOD CLOTTING FACTOR 8; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2-40; TUMOR MARKER;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FACTOR VIII; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84910042619     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-676     Document Type: Article

References (44)

1. Ferlay J, Parkin D, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781. 10.1016/j.ejca.2009.12.014, 20116997.
2. Cancerstats Breast Cancer Statistics http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/. Accessed May 2013, Cancerstats.
3. Rosai J, Sobin L. Tumors of the Mammary Gland 1993, Washington: DC: Armed Forces Institute of Pathology.
4. Gilchrist KW, Gould VE, Hirschl S, Imbriglia JE, Patchefsky AS, Penner DW, Pickren J, Schwartz IS, Wheeler JE, Barnes JM, Mansour EG. Interobserver variation in the identification of breast-carcinoma in intra-mammary lymphatics. Hum Pathol 1982, 13:170-172. 10.1016/S0046-8177(82)80121-4, 7076201.
5. Teel P. Vascular invasion as a prognostic factor in breast carcinoma. Surg Gynecol Obstetrics 1964, 118:1006-1008.
6. Davis BW, Gelber R, Goldhirsch A, Hartmann WH, Hollaway L, Russell I, Rudenstam CM. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol 1985, 16:1212-1218. 10.1016/S0046-8177(85)80033-2, 3905576.
7. Bettelheim R, Mitchell D, Gusterson BA. Immunocytochemistry in the identification of vascular invasion in breast-cancer. J Clin Pathol 1984, 37:364-366. 10.1136/jcp.37.4.364, 498734, 6200505.
8. Pinder SE, Ellis IO, Galea M, Orourke S, Blamey RW, Elston CW. Pathological prognostic factors in breast-cancer.III. Vascular invasion - relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994, 24:41-47. 10.1111/j.1365-2559.1994.tb01269.x, 8144141.
9. de Mascarel I, Bonichon F, Durand M, Mauriac LH, Macgrogan G, Soubeyran I, Picot V, Avril A, Coindre JM, Trojani M. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer 1998, 34:58-65. 10.1016/S0959-8049(97)00344-4, 9624238.
10. McCready DR, Chapman JAW, Hanna WM, Kahn HJ, Murray D, Fish EB, Trudeau ME, Andrulis IL, Lickley LA. Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann Surg Oncol 2000, 7:416-426. 10.1007/s10434-000-0416-z, 10894137.
11. Lee AHS, Pinder SE, Macmillan RD, Mitchell M, Ellis IO, Elston CW, Blamey RW. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 2006, 42:357-362. 10.1016/j.ejca.2005.10.021, 16377180.
12. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, Intra M, Torrisi R, Cardillo A, Campagnoli E, Goldhirsch A, Colleoni M. Invasive ductal carcinoma of the breast with the " triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009, 116:317-328. 10.1007/s10549-008-0206-z, 18839307.
13. Ejlertsen B, Jensen MB, Rank F, Rasmussen BB, Christiansen P, Kroman N, Kvistgaard ME, Overgaard M, Toftdahl DB, Mouridsen HT, . on behalf of the Danish Breast Cancer Cooperative Group Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J Natl Cancer Inst 2009, 101:729-735. 10.1093/jnci/djp090, 19436035, on behalf of the Danish Breast Cancer Cooperative Group.
14. Ragage F, Debled M, MacGrogan G, Brouste V, Desrousseaux M, Soubeyran I, de Lara CT, Muriac L, de Mascarel I. Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?. Cancer 2010, 116:3093-3101. 10.1002/cncr.25137, 20564641.
15. Kato T, Kameoka S, Kimura T, Nishikawa T, Kobayashi M. The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br J Cancer 2003, 88:1900-1908. 10.1038/sj.bjc.6600921, 2741099, 12799634.
16. Mohammed RA, Martin SG, Gill MS, Green AR, Paish EC, Ellis IO. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol 2007, 31:1825-1833. 10.1097/PAS.0b013e31806841f6, 18043036.
17. Mohammed RA, Martin SG, Mahmmod AM, Green AR, Paish EC, Ellis IO. Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. J Pathol 2011, 223:358-365. 10.1002/path.2810, 21171081.
18. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SE, Lichter A, Schnitt SJ. Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Archives Pathol Lab Med 2000, 124:966-978.
19. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann T, Senn HJ. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2009, 20:1319-1329. 10.1093/annonc/mdp322, 2720818, 19535820.
20. Wittekind C, Hutter R, Grenee FL, Klimpfinger M, Sobin LH. TNM Atlas: Illustrated Guideline to the TNM Classification of Malignant Tuomurs 2005, New York: Wiley.
21. Saigo PE, Rosen PP. The application of immunohistochemical stains to identify endothelial-lined channels in mammary carcinoma. Cancer 1987, 59:51-54. 10.1002/1097-0142(19870101)59:1<51::AID-CNCR2820590114>3.0.CO;2-5, 2431757.
22. Van den Eynden G, Van der Auwera I, Van Laere S, Colpaert C, van Dam P, Dirix L, Vermeulen P, Van Marck E. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer 2006, 94:1643-1649. 2361306, 16670715.
23. Hoda SA, Hoda RS, Merlin S, Shamonki J, Rivera M. Issues relating to lymphovascular invasion in breast carcinoma. Adv Anat Pathol 2006, 13:308-315. 10.1097/01.pap.0000213048.69564.26, 17075296.
24. Gujam FJA, Going JJ, Edwards J, Mohammed ZM, McMillan DC. The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Critical Rev Oncol Hematol 2014, 89:231-241.
25. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
26. Mohammed ZMA, Going JJ, McMillan DC, Mallon E, Doughty JC, Edwards J. Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Histopathology 2012, 61:675-684.
27. Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004, 240:306-312. 10.1097/01.sla.0000133355.48672.22, 1356408, 15273556.
28. Yamauchi C, Hasebe T, Iwasaki M, Imoto S, Wada N, Fukayama M, Ochiai A. Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance. Hum Pathol 2007, 38:247-259. 10.1016/j.humpath.2006.07.017, 17056095.
29. Kato T, Kameoka S, Kimura T, Nishikawa T, Kobayashi M. Blood vessel invasion as a predictor of long-term survival for Japanese patients with breast cancer. Breast Cancer Res Treat 2002, 73:1-12. 10.1023/A:1015224703057, 12083626.
30. Kato T, Kimura T, Miyakawa R, Fujii A, Yamamoto K, Kameoka S, Nishikawa T, Kasajima T. Clinicopathologic study associated with long-term survival in Japanese patients with node-negative breast cancer. Br J Cancer 2000, 82:404-411. 10.1054/bjoc.1999.0934, 2363303, 10646896.
31. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008, 14:5158-5165. 10.1158/1078-0432.CCR-07-4756, 18698033.
32. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65. 10.1186/bcr2124, 2575538, 18662380.
33. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569. 10.1056/NEJMoa052933, 16899776.
34. Lauria R, Perrone F, Carlomagno C, Delaurentiis M, Morabito A, Gallo C, Varriale E, Pettinato G, Panico L, Petrella G, Bianco AR, Deplacido S. The prognostic value of lymphatic and blood-vessel invasion in operable breast-cancer. Cancer 1995, 76:1772-1778. 10.1002/1097-0142(19951115)76:10<1772::AID-CNCR2820761014>3.0.CO;2-O, 8625046.
35. Lee AK, Delellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clinical Oncol Official J Am Soc Clinical Oncol 1990, 8:1457-1465.
36. Schoppmann SF, Birner P, Studer P, Breiteneder-Geleff S. Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 2001, 21:2351-2355.
37. Kaiserling E. Immunohistochemical identification of lymph vessels with D2-40 in diagnostic pathology. Pathologe 2004, 25:362-373.
38. Arigami T, Natsugoe S, Uenosono Y, Arima H, Mataki Y, Ehi K, Yanagida S, Ishigami S, Hokita S, Aikou T. Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer 2005, 93:688-693. 10.1038/sj.bjc.6602739, 2361610, 16136051.
39. Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol 2007, 20:183-191. 10.1038/modpathol.3800728, 17206106.
40. Rabban JT, Chen YY. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma. Hum Pathol 2008, 39:175-183. 10.1016/j.humpath.2007.06.018, 18206495.
41. Martin SA, Perez-Reyes N, Mendelsohn G. Angioinvasion in breast carcinoma. An immunohistochem VIII-Related Antigen Cancer 1987, 59:1918-1922.
42. Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. Angiogenesis, assessed by platelet endothelial-cell adhesion molecule antibodies, as indicator of node metastases and survival in breast-cancer. Lancet 1992, 340:1120-1124. 10.1016/0140-6736(92)93150-L, 1279332.
43. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL. Tumor angiogenesis in node-negative breast carcinomas - relationship with epidermal growth-factor receptor, estrogen-receptor, and survival. Breast Cancer Res Treat 1994, 29:109-116. 10.1007/BF00666186, 7517221.
44. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dallapalma P, Caffo C, Barbareschi M, Boracchi P, Marubini E, Pozza F. Tumor microvessel density, P53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast-carcinoma. J Clin Oncol 1994, 12:454-466.